Investors

Marinus is committed to maximizing shareholder value by developing and commercializing ganaxolone for treatment of drug-resistant seizures in both the hospital and home settings.

NASDAQ: MRNS
$ 5.30 +0.19 (3.72%)
Day High: 5.49
Day Low:  4.96
Volume:    1,315,929
4:00 PM ET
Oct 20, 2017

Delayed ~20 min., by eSignal.